Under a co-marketing agreement, Mylan and Biovail will bring a generic version of Schein/Elan's calcium channel blocker Verelan to the market earlier than anticipated, the companies announce May 19. Toronto-based Biovail was the first to file an ANDA for a generic version of the antihypertensive, and Mylan has received FDA approval to manufacture extended-release verapamil capsules in 120 mg, 180 mg and 240 mg strengths. Schein also announced that it would be marketing a generic sustained-release verapamil under a licensing agreement with Elan
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth